dr. J.H.W. (Jeanette) Leusen

dr. J.H.W. (Jeanette) Leusen

Associate Professor
dr. J.H.W. (Jeanette) Leusen
  • Center for Translational Immunology (CTI) Research



Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. She became associate professor and head of the immunotherapy group of the University Medical Center in Utrecht in 2006, and head of the UMAB facility in 2012. She has co-authored more than 120 publications in peer-reviewed journals and is inventor on 10 patent applications. Her group of 24 FTE works on the mechanism of action of therapeutic antibodies, with a special interest in IgA as a novel class of antibody for the treatment of both malignant as infectious disease.


See her research group webpage here >

Side Activities

Dr Leusen is the scientific founder of TigaTx in 2018, a spin-off company on engineered IgA as therapeutic antibody in oncology.

Dr Leusen is senior editor of several Immunology/cancer journals and was organizer of the FASEB meeting on Immunoreceptors of 2014 and 2016, and was vice chair of the Gordon Research Conference on Antibody Biology and Engineering in 2018, and main chair in 2022,

Fellowship and Awards

Dr Leusen holds several grants from Health Holland, KWF, Villa Joep! and industry.

Research Output (136)

The Role of Cytokines in Neutrophil Development, Tissue Homing, Function and Plasticity in Health and Disease

Tsioumpekou Maria, Krijgsman Daniëlle, Leusen Jeanette H W, Olofsen Patricia A Aug 2023, In: Cells. 12 24 p.

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

Stip Marjolein C, Evers Mitchell, Nederend Maaike, Chan Chilam, Reiding Karli R, Damen Mirjam J, Heck Albert J R, Koustoulidou Sofia, Ramakers Ruud, Krijger Gerard C, de Roos Remmert, Souteyrand Edouard, Cornel Annelisa M, Dierselhuis Miranda P, Jansen Marco, de Boer Mark, Valerius Thomas, van Tetering Geert, Leusen Jeanette H W, Meyer-Wentrup Friederike 21 Jul 2023, In: Journal for ImmunoTherapy of Cancer. 11 , p. 1-17

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Chan Chilam, Lustig Marta, Jansen J H Marco, Garcia Villagrasa Laura, Raymakers Leon, Daamen Lois A, Valerius Thomas, van Tetering Geert, Leusen Jeanette H W Jul 2023, In: Cancers. 15

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

Hamdan Firas, Feodoroff Michaela, Russo Salvatore, Fusciello Manlio, Feola Sara, Chiaro Jacopo, Antignani Gabriella, Greco Francesca, Leusen Jeanette, Ylösmäki Erkko, Grönholm Mikaela, Cerullo Vincenzo 16 Mar 2023, In: Molecular Therapy - Oncolytics. 28 , p. 264-276 13 p.

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells

Lustig Marta, Chan Chilam, Jansen J H Marco, Bräutigam Maria, Kölling Max A, Gehlert Carina Lynn, Baumann Niklas, Mester Simone, Foss Stian, Andersen Jan Terje, Bastian Lorenz, Sondermann Peter, Peipp Matthias, Burger Renate, Leusen Jeanette H W, Valerius Thomas 2023, In: Frontiers in Immunology. 14

Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody

Olofsen Patricia A, Stip Marjolein C, Jansen J H Marco, Chan Chilam, Nederend Maaike, Tieland Ralph G, Tsioumpekou Maria, Leusen Jeanette H W Nov 2022, In: Cells. 11

IgG Subclass-Dependent Pulmonary Antigen Retention during Acute IgG-Dependent Systemic Anaphylaxis in Mice

Todorova Biliana, Godon Ophélie, Conde Eva, Gillis Caitlin M., Iannascoli Bruno, Richard-Le Goff Odile, Fiole Daniel, Roumenina Lubka T., Leusen Jeanette H.W., Murphy Andrew J., Macdonald Lynn E., Reber Laurent L., Jönsson Friederike, Bruhns Pierre 1 Oct 2022, In: Journal of immunology (Baltimore, Md. : 1950). 209 , p. 1243-1251 9 p.

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Chan Chilam, Lustig Marta, Baumann Niklas, Valerius Thomas, van Tetering Geert, Leusen Jeanette H.W. 13 Sep 2022, In: Frontiers in Immunology. 13 , p. 1-2

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Baumann Niklas, Arndt Christian, Petersen Judith, Lustig Marta, Rösner Thies, Klausz Katja, Kellner Christian, Bultmann Miriam, Bastian Lorenz, Vogiatzi Fotini, Leusen Jeanette H W, Burger Renate, Schewe Denis M, Peipp Matthias, Valerius Thomas 16 Aug 2022, In: Frontiers in Immunology. 13

Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy:A Novel Anti-Cancer Strategy With IgA Antibodies?

Chan Chilam, Lustig Marta, Baumann Niklas, Valerius Thomas, van Tetering Geert, Leusen Jeanette H W 5 Jul 2022, In: Frontiers in Immunology. 13 , p. 1-21

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet